Rigel announces VEPPANU availability for ER+/HER2- ESR1-mutated breast cancer
Rigel (RIGL) says VEPPANU™ (vepdegestrant) is now available for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.